Configured for how your organisation actually sells
Pharma commercial models differ by size, route to market, therapeutic area and country. Total Pharma Tech adapts segmentation, call planning, compliance rules, incentives and reporting to each of them rather than forcing one template onto every team.
What changes as a field force grows
The capabilities are the same at every scale. What changes is the deployment model, the governance around the field team, and who administers the system day to day.
Emerging & specialty pharma
20–150 reps, one or two products, often one country.
Commercial operations is usually one person who also owns CRM administration, with no appetite for a multi-month IT project. Deployment starts from a standard field model: HCP and HCO records, basic segmentation, call frequency targets and a mobile workflow a rep learns in an afternoon. A single-country pilot goes live in two to four weeks.
Administration stays lean — user management, territory assignment and reporting templates run without engineering support. The constraint arrives later: beyond roughly 150 reps, hand-maintained territories and approval chains stop being reliable.
Mid-size pharma
150–800 reps, several products, often several countries.
The binding constraint stops being adoption and becomes coordination. Reps promote two or three brands, so call plans must balance product priorities inside one territory without doubling visit load. Several countries mean several rule sets, several languages, and a head office that still needs one consolidated view.
The platform answers this with product-level targeting inside a shared call plan, per-country rules on the same workflow, brand and country dashboards from one data model, and territory optimisation that rebalances across products rather than one brand at a time.
Large & global pharma
Multi-affiliate governance, integrations and staged rollouts.
Global organisations are not buying a field application; they are buying a governed system that must coexist with an established commercial stack: affiliate-level data separation with a global reporting layer, single sign-on through your identity provider, integration with Salesforce, Veeva or Dynamics, and a compliance model that can be evidenced country by country.
Rollouts are staged. A pilot affiliate proves the model against agreed measures, then waves of countries go live on shared configuration templates with local overrides. Configuration stays versioned and auditable, because an affiliate's setup may need to be explained during an inspection years later.
In-house, outsourced, distributor-led and medical
Who employs the field team, and who owns the customer relationship, determines what the system must separate, share and report.
In-house field force
Directly employed reps with a single commercial reporting line. Priorities are call plan quality, coaching against real activity, transparent incentives and head-office visibility without extra admin for the field. The practical difference at this scale is integration depth: in-house teams usually want the field application to be the system of record for activity and to feed existing sales and marketing systems.
Contract sales organisations
A CSO runs several clients' products through one field team, sometimes with shared reps and always with separate reporting obligations. The platform separates data per client, produces separate reporting outputs, and gives clients activity evidence they can review without seeing another client's data. Incentive schemes are configured per contract rather than per head-office policy, and territories follow each client's target universe.
Distributor and partner-led models
In many emerging markets the field model runs through distributors and partners rather than direct employees, and the recurring problem is visibility: head office sees sell-in figures but not what happens in the clinic or pharmacy. Partner users get scoped access — their territory, their activity, their reports — while the manufacturer sees aggregated coverage, frequency and structured field feedback. The mobile app works a full day offline for exactly this reason.
MSL and medical affairs teams
Medical science liaisons work to a different rhythm: scientific exchange rather than promotion, longer interactions, key opinion leader mapping, advisory boards and congress activity. The platform supports a medical-only workflow with its own interaction types, reporting lines and access rules, sharing one HCP master record with the commercial team.
Field models differ by what is being prescribed
Call length, stakeholder count, decision unit and purchasing route all change the shape of a call plan. The platform does not assume one shape.
Oncology & specialty care
Small, high-value target lists and long decision cycles. The decision unit is a group — tumour boards, pharmacists, specialist nurses — so the platform models multiple stakeholders per account and tracks engagement across the account rather than a single prescriber. Frequency is lower; call quality matters more.
Cardiology, diabetes & chronic care
Large prescriber universes, often organised in group practices and clinics, where coverage and frequency are the primary levers. Formulary and reimbursement position frequently decides the outcome before the conversation starts, so payer context sits alongside the call plan.
Vaccines & anti-infectives
Campaign and season driven. Demand arrives in windows, purchasing runs through tenders, public health bodies, pharmacies and institutions, and coverage targets follow a calendar rather than a rolling quarter. The platform supports campaign-specific plans and non-prescriber customer types.
Medical devices & diagnostics
Selling is linked to a procedure, an evaluation or an installation. Stakeholders are clinical and technical, decisions run through procurement and committee cycles, and field teams carry training and service activity as well as promotion, captured as distinct activity types with their own reporting.
The same platform, five different jobs
Access, screens and reports are configured by role, so nobody carries a view they do not need.
| Role | What they get |
|---|---|
| Field representative | An offline-capable daily plan with sequenced visits, HCP context, approved material and AI next-best-action. Interaction capture is short and structured, pre-call planning is generated from the last visit, and incentive position is always visible. |
| First-line manager | Live team activity instead of a month-old report: coverage against plan, visit quality signals, adherence flags and coaching prompts before a ride-along. Approvals, territory changes and plan overrides run in the same workflow, with the reasoning recorded. |
| Commercial director | Territory balance, potential coverage, effort allocation and effectiveness trends across brands, countries and affiliates on one dashboard, with every figure traceable to source activity. |
| Marketing | Reach, frequency and message pull-through by segment, plus evidence of which approved content is actually used in the field. Structured field signals rather than anecdote ground the next cycle's targeting decisions. |
| Compliance & medical-legal review | Country-specific interaction rules enforced inside the workflow, complete audit trails of changes and approvals, exportable evidence for inspections, and controls over what may be provided or discussed. Role-based access keeps commercial and medical data separate where policy requires it. |
One platform, four sets of operational realities
Regional differences are rarely about features. They are about connectivity, regulation, language, incentive currency and what may legally change hands on a call.
North America
Connectivity is rarely the constraint; regulation and access are. Transparency reporting and sample accountability need activity data that is complete and defensible at rep level, so promotion, transfers of value and sample movements stay as separate, exportable records. Payer and formulary context belongs on the call plan, and large integrated health systems need account-level planning alongside individual prescribers.
Europe
Rules are set per country, not per region. Interaction limits, disclosure requirements and what counts as acceptable promotion differ market to market, so rule sets are configured per affiliate and applied to the same workflow. Personal data handling follows GDPR-aligned consent, retention and erasure processes, with EU residency available. Local-language interfaces and multi-currency incentives are normal rather than exceptional.
Asia-Pacific & MENA
Connectivity varies within countries, not just between them, so the mobile application works a full day offline and syncs on return. Field models often run through distributors, tenders and public health programmes, which means partner scopes, non-prescriber customer types and campaign-based planning. Right-to-left language support and local-currency incentives are part of the deployment.
Latin America
High-frequency coverage across clinics, pharmacies and distributors, with distributor activity visible in the manufacturer's reporting layer. Multi-currency incentives and volatile inflation make transparent, auditable incentive calculation more important than elaborate scheme design. Spanish and Portuguese interfaces and low-bandwidth field use shape the rollout.
Map the platform to your commercial model
Tell us your organisation size, route to market and the countries involved, and we will show how one configuration model covers them — in a working sandbox, not a generic walkthrough.